Back

Vericiguat improves MRI-assessed coronary endothelial function in patients with metabolic syndrome or type 2 diabetes mellitus

29 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Improved targeting of risk factors and residual risk Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Tarek Harb

The Johns Hopkins University School of Medicine, Baltimore (United States of America)

6 More presentations in this session

Presentation thumbnail
Association of dysglycaemic indices with coronary anatomical complexity in non-diabetic patients presenting with acute coronary syndrome
Doctor M. Merry (Ismailia, EG)
Abstract
Presentation thumbnail
Lipid management in patients with coronary artery disease at risk of a first major atherosclerotic cardiovascular event: findings from the VESALIUS-REAL global study
Professor G. De Ferrari (Turin, IT)
Abstract
Presentation thumbnail
Effects of residual risk–targeted therapies on coronary plaque regression: a network meta-analysis of 40 studies
Doctor M. Galli (Rome, IT)
Abstract
Presentation thumbnail
The hypothyroidism paradox: treated thyroid status as a long-term catalyst for LDL-C target attainment post-percutaneous coronary intervention
Miss T. Simonneau (Cordoba, ES)
Abstract
Presentation thumbnail
Impact of a personalized, fire-to-target lipid-lowering strategy in patients with acute coronary syndrome
Doctor J. Herrera (Cordoba, ES)
Abstract

Access the full session

Session thumbnail
Improved targeting of risk factors and residual risk

The Event

Event poster

ESC Congress 2026

29 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Assessment of cardiac reverse remodeling in patients with LV systolic dysfunction receiving vericiguat in addition to optimal GDMT
13 December 2024
thumbnail
Congress Presentation
First-degree relatives of type-2 diabetic patients and dysglycaemic patients have impaired endothelial function due to decreased bioavailability of nitric oxide
27 August 2021
thumbnail
Congress Presentation
Evolocumab rapidly reverses impaired coronary endothelial function in six weeks in people living with HIV and in patients with dyslipidemia
2 September 2019
thumbnail
Congress Presentation
Metabolic syndrome contributes to the pulmonary arterial dysfunction in pulmonary hypertension in heart failure with preserved ejection fraction
31 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources